IBDEI1AG ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,22823,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,22823,1,5,0)
 ;;=5^Hodgkin's Lymphoma, Unpsec Type & Site
 ;;^UTILITY(U,$J,358.3,22823,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,22824,0)
 ;;=785.6^^125^1397^89
 ;;^UTILITY(U,$J,358.3,22824,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22824,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,22824,1,5,0)
 ;;=5^Lymphadenopathy
 ;;^UTILITY(U,$J,358.3,22824,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,22825,0)
 ;;=200.20^^125^1397^90
 ;;^UTILITY(U,$J,358.3,22825,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22825,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,22825,1,5,0)
 ;;=5^Lymphoma,Burkitt's,Site Unspec
 ;;^UTILITY(U,$J,358.3,22825,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,22826,0)
 ;;=202.00^^125^1397^92
 ;;^UTILITY(U,$J,358.3,22826,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22826,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,22826,1,5,0)
 ;;=5^Lymphoma,Low-Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,22826,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,22827,0)
 ;;=200.10^^125^1397^91
 ;;^UTILITY(U,$J,358.3,22827,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22827,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,22827,1,5,0)
 ;;=5^Lymphoma,Int or High Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,22827,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,22828,0)
 ;;=273.3^^125^1397^93
 ;;^UTILITY(U,$J,358.3,22828,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22828,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,22828,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,22828,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,22829,0)
 ;;=203.00^^125^1397^103
 ;;^UTILITY(U,$J,358.3,22829,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22829,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,22829,1,5,0)
 ;;=5^Multiple Myeloma w/o Remission
 ;;^UTILITY(U,$J,358.3,22829,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,22830,0)
 ;;=203.01^^125^1397^105
 ;;^UTILITY(U,$J,358.3,22830,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22830,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,22830,1,5,0)
 ;;=5^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,22830,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,22831,0)
 ;;=238.6^^125^1397^108
 ;;^UTILITY(U,$J,358.3,22831,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22831,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,22831,1,5,0)
 ;;=5^Plasmacytoma NOS
 ;;^UTILITY(U,$J,358.3,22831,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,22832,0)
 ;;=205.00^^125^1397^4
 ;;^UTILITY(U,$J,358.3,22832,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22832,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,22832,1,5,0)
 ;;=5^AML w/o Remission
 ;;^UTILITY(U,$J,358.3,22832,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,22833,0)
 ;;=205.01^^125^1397^6
 ;;^UTILITY(U,$J,358.3,22833,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22833,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,22833,1,5,0)
 ;;=5^AML,In Remission
 ;;^UTILITY(U,$J,358.3,22833,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,22834,0)
 ;;=205.10^^125^1397^19
 ;;^UTILITY(U,$J,358.3,22834,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22834,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,22834,1,5,0)
 ;;=5^CML w/o Remission
 ;;^UTILITY(U,$J,358.3,22834,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,22835,0)
 ;;=205.11^^125^1397^21
 ;;^UTILITY(U,$J,358.3,22835,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22835,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,22835,1,5,0)
 ;;=5^CML,In Remission
 ;;^UTILITY(U,$J,358.3,22835,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,22836,0)
 ;;=289.0^^125^1397^55
 ;;^UTILITY(U,$J,358.3,22836,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22836,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,22836,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;
 ;;$END ROU IBDEI1AG
